H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on ATAI Life Sciences (ATAI – Research Report) today and set a price target of $20.00. The company’s shares closed yesterday at $2.01.
Trucchio covers the Healthcare sector, focusing on stocks such as uniQure, ATAI Life Sciences, and Alnylam Pharma. According to TipRanks, Trucchio has an average return of -13.6% and a 33.83% success rate on recommended stocks.
ATAI Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $15.33, representing a 662.69% upside. In a report released on January 9, Canaccord Genuity also maintained a Buy rating on the stock with a $11.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on ATAI Life Sciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $24 thousand and a GAAP net loss of $33.89 million. In comparison, last year the company earned a revenue of $266 thousand and had a GAAP net loss of $31.16 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine.
Read More on ATAI:
- Here’s What You Missed in Cannabis This Week
- IntelGenx receives fourth, final loan tranche from Atai Life Sciences
- Atai Life Sciences price target lowered to $11 from $27 at Canaccord
- Atai Life Sciences price target lowered to $10 from $18 at Loop Capital
- Atai Life Sciences price target lowered to $10 from $20 at Citi